Cardinal Health Inc.
) entered an agreement to buy privately-held AccessClosure Inc.
for $320 million. AccessClosure is a manufacturer and distributor
of extravascular closure devices in the U.S. with $80 million in
annual sales. It is popular for its Mynx suite of
patient-friendly vascular closure devices.
BARD C R INC (BCR): Free Stock Analysis
BECTON DICKINSO (BDX): Free Stock Analysis
CARDINAL HEALTH (CAH): Free Stock Analysis
COOPER COS (COO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Following the announcement, shares of Cardinal Health escalated
1.5% to close at $71.31 yesterday. The acquisition is expected to
be completed by early June this year and it is not going to have
a material impact on the company's earnings in fiscal 2014 but
modestly accretive to the same in fiscal 2015.
AccessClosure's Mynx is a clinically proven product helpful in
sealing the femoral artery using an effective sealant that
dissolves within a month, leaving no marks of a healed artery. It
also helps patients to ambulate safely within a short time,
meaning they could return home very soon.
Cardinal Health posted adjusted earnings per share of 90 cents
for the second quarter of fiscal 2014, which surpassed the Zacks
Consensus Estimate by 7 cents but fell short of the year-ago
level of 93 cents by 3.2% due to lower revenues.
Net adjusted earnings slid 1.3% to $313 million from $317 million
in the second quarter of fiscal 2013. On a reported basis, net
earnings decreased to $275 million or 79 cents per share in the
quarter from $303 million or 88 cents per share in the year-ago
Revenues in the quarter went down about 12% to $22,240 million,
due to lower revenues from the Pharmaceutical segment.
Nevertheless, the top line beat the Zacks Consensus Estimate of
For fiscal 2014, Cardinal Health raised its forecast for adjusted
earnings per share to the band of $3.75 to $3.85 from the earlier
guidance of $3.62 to $3.72. Management cited the company's
efficient operating performance as the reason behind the upgraded
guidance. The current Zacks Consensus Estimate of $3.83 for the
year lies within the guided range.
Cardinal Health currently has a Zacks Rank #2 (Buy). Other Zacks
Rank #2 (Buy) stocks from the medical/dental supplies industry
CR Bard Inc.
Becton, Dickinson and Company
The Cooper Companies Inc.